Comparison

CJC-1295 vs. Ipamorelin

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

CJC-1295

Synthetic analogue of growth-hormone-releasing hormone (GHRH), modified for extended half-life via a Drug Affinity Complex (DAC) binding to albumin. Acts on the pituitary GHRH receptor and stimulates endogenous growth-hormone release.

Ipamorelin

Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.

Evidence base

Highest evidence

Human trial

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	CJC-1295	Ipamorelin
Germany	Unapproved	Unapproved
United States	Research only	Unapproved

Full entries

Frequently asked questions

What is the difference between CJC-1295 and Ipamorelin?: CJC-1295 is classified as "Growth", while Ipamorelin is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, CJC-1295 or Ipamorelin?: The highest available evidence level is "Human trial" for CJC-1295 and "Human RCT" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of CJC-1295 and Ipamorelin in Germany and the United States?: Germany: CJC-1295 — Unapproved, Ipamorelin — Unapproved. United States: CJC-1295 — Research only, Ipamorelin — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

CJC-1295

Ipamorelin

Germany

Unapproved

United States

Research only

Unapproved

Frequently asked questions

What is the difference between CJC-1295 and Ipamorelin?

CJC-1295 is classified as "Growth", while Ipamorelin is classified as "Growth". CJC-1295: Long-acting synthetic GHRH analogue modified for albumin binding (DAC). Stimulates endogenous growth-hormone release. Pharmacodynamic effect established in small human studies; clinical endpoint trials are missing. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, CJC-1295 or Ipamorelin?

The highest available evidence level is "Human trial" for CJC-1295 and "Human RCT" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of CJC-1295 and Ipamorelin in Germany and the United States?

Germany: CJC-1295 — Unapproved, Ipamorelin — Unapproved. United States: CJC-1295 — Research only, Ipamorelin — Unapproved. These are factual summaries with source and review date on the individual pages.